This polymorphism is related to the promotion of binding between oncoprotein E6 and several cellular proteins, such as P53 and apoptosis-inducing factors in C33-A cell lines, leading to the formation of complexes that inactivate important functions in these cells, such as tumor suppression, apoptosis, and regulation of mitosis, leading to tumor formation, epithelial degradation and, therefore, carcinomas [10-13, 15, 16]. The gene discussed is TP53; the disease is neoplasm.